JK-1201I for triple negative breast cancer with brain metastases
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called JK-1201I for women with triple negative breast cancer that has spread to the brain. It is for patients who have already had chemotherapy and are looking for more treatment options to control their brain tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- You have been diagnosed with triple negative breast cancer that has spread to your brain.
- You must have had at least one type of chemotherapy before (with drugs called anthracyclines and taxanes) for advanced disease.
- You should be able to handle daily activities well (ECOG score 0 or 1).
- You cannot have had previous treatment with irinotecan or similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This study tests a combination of radiation therapy, chemotherapy drugs (platinum-based), and two immunotherapy medications (adebrelimab and bevacizumab) for triple-negative breast cancer that has spread to the brain. The goal is to shrink tumors and improve survival when surgery or standard radiation alone isn't an option.
This trial tests a new drug, MR001, for people with triple-negative breast cancer that has come back or spread. It's for those who've already tried at least one type of treatment.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a new drug, JK-1201I, against a standard treatment (topotecan) for people with extensive-stage small cell lung cancer that came back after platinum-based chemotherapy. It aims to see if the new drug works better at controlling the cancer.
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
Hear when a new Brain Metastasases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.